Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed stage IIB-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer * No borderline ovarian tumors * Residual disease allowed * Fine needle aspiration showing an adenocarcinoma is allowed instead of open or true-cut biopsy if the following are true: * Presence of pelvic mass AND * Omental cake or other metastasis larger than 2 cm in the upper abdomen unless proven stage IV disease AND * Serum CA 125/carcinoembryonic antigen ratio at least 25 (if less than 25, a barium enema or colonoscopy and gastroscopy or radiological examination of the stomach should be negative for primary tumor within 6 weeks of study) AND * Normal mammography within 6 weeks of study PATIENT CHARACTERISTICS: Age: * 18 to 75 Performance status: * ECOG 0-1 Life expectancy: * At least 12 weeks Hematopoietic: * Granulocyte count at least 2,000/mm\^3 * Platelet count at least 150,000/mm\^3 Hepatic: * Not specified Renal: * Creatinine no greater than upper limit of normal Cardiovascular: * No clinically relevant atrial or ventricular arrhythmias * No myocardial infarction (MI) within the past 6 months (pretreatment ECG as only evidence of MI allowed) * No history of second- or third-degree heart blocks unless pacemaker implanted * History of first-degree heart block allowed Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No complete bowel obstruction * No prior allergic reaction to drugs containing Cremophor EL or compounds chemically related to study drugs * No condition that would preclude high-volume saline diuresis * No significant neurologic or psychiatric disorder that would preclude study compliance * No active uncontrolled infection * No neuropathy greater than grade 1 * No pre-existing hearing loss greater than grade 1 * No other concurrent serious illness or medical condition that would preclude study participation * No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent biological response modifiers or immunotherapy * No concurrent prophylactic colony-stimulating factors (CSFs) * Concurrent therapeutic CSFs allowed Chemotherapy: * No prior chemotherapy for ovarian cancer * No other concurrent cytotoxic agents Endocrine therapy: * No concurrent anticancer hormonal therapy Radiotherapy: * No prior radiotherapy for ovarian cancer Surgery: * No more than 6 weeks since prior planned pre-chemotherapy surgery for ovarian cancer * Planned interval debulking allowed * Concurrent second-look surgery allowed Other: * No prior non-surgical therapy for ovarian cancer * No other concurrent investigational drug therapy * No other concurrent anticancer treatment * Concurrent enrollment on CAN-NCIC-OV13/EORTC 55971 allowed